Gilead Sciences (GILD) Change in Taxes (2009 - 2026)
Gilead Sciences (GILD) posted Change in Taxes of -$29.0 million for Q1 2026, up 78.36% quarter-over-quarter from -$134.0 million in Q4 2025, and up 94.75% year-on-year from -$14.9 million in Q1 2025.
Gilead Sciences (GILD) Change in Taxes (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Change in Taxes for 18 consecutive years, with -$29.0 million the latest figure, recorded in Q1 2026.
- Change in Taxes for Q1 2026 came in at -$29.0 million, up 94.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.6 billion (down 47.3% YoY), and the FY2025 annual result was -$2.1 billion, down 187.98% from the prior year.
- Change in Taxes was -$29.0 million for Q1 2026 at Gilead Sciences, up from -$134.0 million in the prior quarter.
- Over five years, Change in Taxes peaked at $536.0 million in Q4 2024 and troughed at -$1.3 billion in Q2 2025.
- Average Change in Taxes over 5 years is -$294.2 million, with a median of -$134.0 million recorded in 2025.
- The widest YoY moves for Change in Taxes: up 176.79% in 2024, down 4082.14% in 2024.
- Over 5 years, Change in Taxes stood at $119.0 million in 2022, then sank by 686.55% to -$698.0 million in 2023, then soared by 176.79% to $536.0 million in 2024, then slumped by 125.0% to -$134.0 million in 2025, then jumped by 78.36% to -$29.0 million in 2026.
- Per Business Quant data, the three most recent Change in Taxes figures were -$29.0 million in Q1 2026, -$134.0 million in Q4 2025, and -$122.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -81.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -526.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 71.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -29.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 18.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.00 Mn |
| Mar 31, 2026 | -29.00 Mn |
| Dec 31, 2025 | -134.00 Mn |
| Dec 31, 2025 | -134.00 Mn |
| Sep 30, 2025 | -122.00 Mn |
| Sep 30, 2025 | -122.00 Mn |
| Jun 30, 2025 | -1.30 Bn |
| Jun 30, 2025 | -1.30 Bn |
| Mar 31, 2025 | -552.00 Mn |
| Mar 31, 2025 | -552.00 Mn |
| Dec 31, 2024 | 536.00 Mn |
| Dec 31, 2024 | 536.00 Mn |
| Sep 30, 2024 | 111.00 Mn |
| Sep 30, 2024 | 111.00 Mn |
| Jun 30, 2024 | -1.17 Bn |
| Jun 30, 2024 | -1.17 Bn |
| Mar 31, 2024 | -208.00 Mn |
| Mar 31, 2024 | -208.00 Mn |
| Dec 31, 2023 | -698.00 Mn |
| Dec 31, 2023 | -698.00 Mn |